Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization
暂无分享,去创建一个
D. Scherman | F. Prósper | Z. Izsvák | Z. Ivics | G. Thumann | S. Johnen | J. R. Rodriguez-Madoz | A. García-Layana | C. Marie | J. Bezunartea | A. Sebe | María Hernández | S. Recalde | L. García-García | C. Miskey | Sabine Diarra | Séverine Pouillot | Martina Kropp | P. Fernandez-Robredo | J. R. Rodríguez-Madoz | S. Diarra | P. Fernández-Robredo | Csaba Miskey
[1] A. Penman,et al. Prevalence of Age-Related Maculopathy , 2020 .
[2] Z. Ivics,et al. Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. , 2018, Current opinion in genetics & development.
[3] Mark S. Humayun,et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration , 2018, Science Translational Medicine.
[4] Adnan Tufail,et al. Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration , 2018, Nature Biotechnology.
[5] Z. Izsvák,et al. Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] D. Scherman,et al. The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells , 2017, Molecular therapy. Nucleic acids.
[7] Z. Izsvák,et al. Gene Therapy with the Sleeping Beauty Transposon System. , 2017, Trends in genetics : TIG.
[8] T. Peto,et al. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015 , 2017, BMJ Open.
[9] Z. Izsvák,et al. Wide Awake and Ready to Move: 20 Years of Non-Viral Therapeutic Genome Engineering with the Sleeping Beauty Transposon System. , 2017, Human gene therapy.
[10] Gretchen A. Stevens,et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. , 2017, The Lancet. Global health.
[11] S. Temple,et al. Development of a Refined Protocol for Trans-scleral Subretinal Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes. , 2017, Journal of visualized experiments : JoVE.
[12] D. Scherman,et al. Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery , 2017, Molecular therapy. Nucleic acids.
[13] C. Sorenson,et al. PEDF expression affects retinal endothelial cell proangiogenic properties through alterations in cell adhesive mechanisms. , 2017, American journal of physiology. Cell physiology.
[14] T. Ciulla,et al. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration , 2017, Expert opinion on emerging drugs.
[15] Z. Izsvák,et al. Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side , 2017, Critical reviews in biochemistry and molecular biology.
[16] D. Scherman,et al. Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids , 2017, Molecular therapy. Nucleic acids.
[17] L. Zechiedrich,et al. Advances in Non-Viral DNA Vectors for Gene Therapy , 2017, Genes.
[18] Z. Izsvák,et al. Sleeping Beauty transposition: from biology to applications , 2017, Critical reviews in biochemistry and molecular biology.
[19] T. Shiina,et al. Successful Transplantation of Retinal Pigment Epithelial Cells from MHC Homozygote iPSCs in MHC-Matched Models , 2016, Stem cell reports.
[20] Mark S. Humayun,et al. Subretinal implantation of a monolayer of human embryonic stem cell-derived retinal pigment epithelium: a feasibility and safety study in Yucatán minipigs , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.
[21] Heng-yu Zhang,et al. Comparison of peripheral iridectomy methods for posterior chamber phakic intraocular lens implantation in patients with brown irides , 2016, BMC Ophthalmology.
[22] D. Clegg,et al. An Innovative Surgical Technique for Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelium in Yucatan Mini Pigs: Preliminary Results. , 2016, Ophthalmic surgery, lasers & imaging retina.
[23] Sofia M. Calado,et al. pEPito-driven PEDF Expression Ameliorates Diabetic Retinopathy Hallmarks. , 2016, Human gene therapy methods.
[24] A. García-Layana,et al. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. , 2016, Biochemical pharmacology.
[25] Wei Chen,et al. Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4+ T Cells , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] Z. Izsvák,et al. Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In Vivo , 2015, BioMed research international.
[27] H. Uusitalo,et al. Ultrathin Polyimide Membrane as Cell Carrier for Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelium , 2015, PloS one.
[28] L. M. Sadaba-Echarri,et al. Modifying Choroidal Neovascularization Development with a Nutritional Supplement in Mice , 2015, Nutrients.
[29] A. Aiuti,et al. Clinical applications of gene therapy for primary immunodeficiencies. , 2015, Human gene therapy.
[30] Kristian Vlahovicek,et al. Genomation: a Toolkit to Summarize, Annotate and Visualize Genomic Intervals , 2015, Bioinform..
[31] J. Roider,et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis , 2014, British Journal of Ophthalmology.
[32] Anne Louise Askou,et al. Development of gene therapy for treatment of age‐related macular degeneration , 2014, Acta ophthalmologica.
[33] R. Klein,et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.
[34] M. Mandai,et al. Characterization of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Sheets Aiming for Clinical Application , 2014, Stem cell reports.
[35] G. Lutty,et al. VEGF Receptor Blockade Markedly Reduces Retinal Microglia/Macrophage Infiltration into Laser-Induced CNV , 2013, PloS one.
[36] P. Coffey,et al. Development of human embryonic stem cell therapies for age-related macular degeneration , 2013, Trends in Neurosciences.
[37] A. García-Layana,et al. Transforming Growth Factor-Beta Inhibition Reduces Progression of Early Choroidal Neovascularization Lesions in Rats: P17 and P144 Peptides , 2013, PloS one.
[38] N. Ershov,et al. Rat retinal transcriptome: Effects of aging and AMD-like retinopathy , 2013, Cell cycle.
[39] A. García-Layana,et al. Azithromycin reduces inflammation in a rat model of acute conjunctivitis , 2013, Molecular vision.
[40] F. Mavilio,et al. Mechanisms of retroviral integration and mutagenesis. , 2013, Human gene therapy.
[41] N. Scott,et al. RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2013, Retina.
[42] Z. Izsvák,et al. Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] J. Jonas,et al. Cytokine concentration in aqueous humour of eyes with exudative age‐related macular degeneration , 2012, Acta ophthalmologica.
[44] Z. Izsvák,et al. Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. , 2012, Investigative ophthalmology & visual science.
[45] Usha Chakravarthy,et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.
[46] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[47] Kevin A. T. Silverstein,et al. TAPDANCE: An automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data , 2012, BMC Bioinformatics.
[48] Z. Izsvák,et al. Retargeting transposon insertions by the adeno-associated virus Rep protein , 2012, Nucleic acids research.
[49] Michel Sadelain,et al. Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.
[50] A. García-Layana,et al. Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. , 2011, Investigative ophthalmology & visual science.
[51] Z. Izsvák,et al. Nonviral gene delivery with the sleeping beauty transposon system. , 2011, Human gene therapy.
[52] R. Khokha,et al. Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. , 2011, Investigative ophthalmology & visual science.
[53] Alessandro Guffanti,et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. , 2010, Blood.
[54] S. Ekker,et al. Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[55] R. K. Murthy,et al. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells , 2010, Molecular vision.
[56] W. Drexler,et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study , 2010, British Journal of Ophthalmology.
[57] Frederik De Smet,et al. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way , 2009, Nature Reviews Clinical Oncology.
[58] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[59] P. Walter,et al. Preservation of photoreceptors in dystrophic RCS rats following allo- and xenotransplantation of IPE cells , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[60] Magali Saint-Geniez,et al. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.
[61] P. Debré,et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. , 2007, The Journal of clinical investigation.
[62] P. Wiedemann,et al. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. , 2007, Investigative ophthalmology & visual science.
[63] J. Kowalak,et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. , 2007, Investigative ophthalmology & visual science.
[64] G. Gao,et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. , 2006, Journal of molecular endocrinology.
[65] E. T. Ek,et al. Pigment epithelium-derived factor: a multimodal tumor inhibitor , 2006, Molecular Cancer Therapeutics.
[66] K. Bartz-Schmidt,et al. Iris pigment epithelial translocation in the treatment of exudative macular degeneration: a 3-year follow-up. , 2006, Archives of ophthalmology.
[67] R. Lutz,et al. Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. , 2005, Investigative ophthalmology & visual science.
[68] Lois E. H. Smith,et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. , 2005, Investigative ophthalmology & visual science.
[69] P. Campochiaro,et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. , 2005, Human gene therapy.
[70] Zoltán Ivics,et al. Sleeping beauty transposition: biology and applications for molecular therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[71] L. Montuenga,et al. Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. , 2004, Experimental eye research.
[72] P. McGuire,et al. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition , 2003, Progress in Retinal and Eye Research.
[73] C. Barnstable,et al. PEDF: a multifaceted neurotrophic factor , 2003, Nature Reviews Neuroscience.
[74] G. Thakker,et al. Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells , 2003, Molecular Cancer.
[75] Daniel F Voytas,et al. Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. , 2002, Journal of molecular biology.
[76] R. Lund,et al. Preservation of visual responsiveness in the superior colliculus of RCS rats after retinal pigment epithelium cell transplantation , 2002, Neuroscience.
[77] S. Kochanek,et al. Autologous transplantation of genetically modified iris pigment epithelial cells: A promising concept for the treatment of age-related macular degeneration and other disorders of the eye , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[78] P. Campochiaro,et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.
[79] R. Hilgers,et al. Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: a pilot study. , 2002, American journal of ophthalmology.
[80] P. Campochiaro,et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). , 2001, Human gene therapy.
[81] Ronald Klein,et al. The prevalence of age-related macular degeneration and associated risk factors. , 2001, Archives of ophthalmology.
[82] P Esser,et al. Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. , 2000, Archives of ophthalmology.
[83] B. Kirchhof,et al. Iris pigment epithelial cell translocation in exudative age-related macular degeneration , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.
[84] M. Kay,et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system , 2000, Nature Genetics.
[85] K. Heimann,et al. The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells. , 1998, Experimental eye research.
[86] J. P. Schwartz,et al. Pigment epithelium‐derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes , 1997, Journal of neuroscience research.
[87] P. Gouras,et al. Tolerance of human fetal retinal pigment epithelium xenografts in monkey retina , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.
[88] R. Klein,et al. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.
[89] J. Tombran-Tink,et al. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. , 1991, Experimental eye research.
[90] T. Okada. Recent progress in studies of the transdifferentiation of eye tissue in vitro. , 1983, Cell differentiation.
[91] K. Yasuda,et al. A demonstration of a switch of cell type in human fetal eye tissues in vitro: pigmented cells of the iris or the retina can transdifferentiate into lens. , 1978, Experimental eye research.
[92] H. Schatz. Sloughing of skin following fluorescein extravasation. , 1978, Annals of ophthalmology.
[93] H. Einsele,et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors , 2017, Leukemia.
[94] Z. Izsvák,et al. Sleeping Beauty Transposition. , 2015, Microbiology spectrum.
[95] Sonia Mehta,et al. Age-Related Macular Degeneration. , 2015, Primary care.
[96] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[97] F. Cogé,et al. The role of the matrix metalloproteinases during in vitro vessel formation , 2004, Angiogenesis.
[98] H. Grossniklaus,et al. Choroidal neovascularization. , 2004, American journal of ophthalmology.
[99] G. Thumann,et al. Development and cellular functions of the iris pigment epithelium. , 2001, Survey of ophthalmology.
[100] A. Reiner,et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.
[101] K. Ohno-Matsui,et al. SUBRETINAL BLEEDING WITHOUT CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA: A Sign of New Lacquer Crack Formation , 1996, Retina.
[102] D. Ingber,et al. Inhibition of angiogenesis. , 1992, Seminars in cancer biology.
[103] T. Okada. Cellular metaplasia or transdifferentiation as a model for retinal cell differentiation. , 1980, Current topics in developmental biology.